查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439987

数位治疗 - 全球市场考量、竞争状况、市场预测 (2030)

Digital Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按订单生产 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

预计2024-2030年期间，全球数位治疗市场规模将以27.73%的复合年增长率成长。糖尿病、精神疾病、癌症和心臟衰竭 (HF) 等慢性疾病的盛行率不断上升，以及行动科技、穿戴式装置、人工智慧、装置学习和数据分析的不断进步，推动了对数位疗法的需求。科技正在推动更复杂、更有效的数位治疗解决方案的开发。许多国家的医疗保健费用正在稳定增加。数位疗法透过远端提供高效的医疗保健、减少频繁去医院的需要以及预防与慢性病相关的昂贵併发症，提供了降低医疗成本的机会。监管支援、医疗保健专业人士的接受度不断提高、健康保险覆盖范围、策略合作伙伴关係和投资等将有助于2024-2030年预测期内数位治疗市场的整体成长，这些是推动市场成长的主要因素。

数位治疗市场动态

根据International Diabetes Federation（2022）的数据，2021 年全球约有 5.37 亿人患有糖尿病。根据上述资料，预计到2030年，糖尿病患者总数将增加至约6.43亿，到2045年将增加至约7.83亿。

数位治疗(DTx) 应用程序，例如Blue Star、Diabeo System、Livongo Diabetes Program 和Tidepool，使用基于Web 的应用程式和云端平台，为包括糖尿病在内的行为可改变的慢性疾病提供循证的个人化治疗。护理管理。DTx 透过促进患者积极参与、改变生活方式、全面的医疗照护和定期监测血糖状态，提高糖尿病管理中的患者依从性、治疗成功率和经济成果。因此，糖尿病盛行率的不断上升增加了对用于糖尿病管理和治疗的数位治疗软体的需求，从而推动了整个数位治疗市场的发展。

智慧型手机在已开发市场和新兴市场的渗透率不断提高，患者和医疗保健提供者对数位医疗技术的承受能力，以及对以患者为中心的护理和综合医疗系统不断增长的需求，预计将推动该市场的发展。Kepios估计，2021年4月全球有42.7亿人使用互联网，占世界人口的60%以上。随着这个数字的增加，预计人们对智慧健康追踪的意识也会增强。此外，COVID-19 大流行、有益的监管措施、报销的早期迹像以及慢性病盛行率的上升预计将推动市场扩张。

领先的关键参与者专注于开发这种先进的技术支援的软体，使医生和患者可以轻鬆访问，预计将在预测期内推动市场发展。例如，2022 年 7 月，AmerisourceBergen Corporation 宣布推出 DTx Connect，这是一个完全整合的订购、配药和履行平台，旨在促进患者获得医生订购的治疗和诊断服务。该平台与电子病历 (EMR) 集成，使医生可以轻鬆获得处方药和非处方药。

因此，上述因素正在推动2024-2030年预测期内数位治疗市场的成长。

然而，网路安全和隐私问题、不稳定的支付模式等可能会抑制数位治疗市场的成长。

数位治疗市场细分分析

在数位治疗市场的适应症领域，肥胖类别预计将在 2023 年获得可观的收入占有率。这是由于世界各地肥胖统计数据不断增加。

该报告提供了全球数位治疗市场的研究和分析，包括市场规模和预测、驱动因素和挑战以及公司和产品概况。

目录

第一章数位治疗市场报告简介

第二章数位治疗市场执行摘要

  • 调查范围
  • 市场概况
  • 竞争评估

第三章 监管分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第四章数位治疗市场主要因素分析

  • 数位治疗市场的驱动因素
  • 数位治疗市场的限制与挑战
  • 数位治疗市场机会

第五章波特数位治疗市场五力分析

第六章 数位治疗市场布局

  • 依用途
    • 预防
    • 管理
    • 治疗
  • 依指示
    • 糖尿病
    • 肥胖
    • 心血管疾病
    • 呼吸系统疾病
    • 其他
  • 区域
    • 北美数位治疗市场规模（2021-2030）
    • 欧洲数位治疗市场规模（2021-2030）
    • 亚太地区数位治疗市场规模（2021-2030）
    • 其他地区数位治疗市场规模（2021-2030）

第 7 章：数位治疗市场公司与产品概况

  • Limbix Health, Inc.
  • GAIA AG
  • BigHealth
  • DarioHealth Corp
  • HYGIEIA
  • Akili, Inc
  • Pear Therapeutics (US), Inc.
  • CANARY HEALTH
  • Noom, Inc.
  • Omada Health Inc.
  • Welldoc, Inc.
  • 2Morrow, Inc
  • ResMed
  • Teladoc Health, Inc.
  • Fitbit Health Solutions

第8章 KOL观点

第9章 专案方法

第10章 关于 DelveInsight

第11章 免责声明与联络我们

Product Code: DIMDCL0668

Digital Therapeutics Market By Application (Prevention, Management, And Treatment), Indication (Diabetes, Obesity, Cardiovascular Diseases, Respiratory Diseases, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing accessibility of virtual care and shifting focus among the population on lowering the healthcare cost

The global digital therapeutics market is estimated to grow at a CAGR of 27.73% during the forecast period from 2024 to 2030. The demand for digital therapeutics is being boosted by the increasing prevalence of chronic diseases such as diabetes, mental illness, cancer, and heart failure (HF), advancements in technology such as the continuous advancements in mobile technology, wearable devices, artificial intelligence, machine learning, and data analytics have facilitated the development of more sophisticated and effective digital therapeutics solutions. Rising healthcare cost as healthcare costs have been steadily increasing in many countries. Digital therapeutics offer an opportunity to reduce healthcare expenses by providing remote and efficient healthcare delivery, reducing the need for frequent hospital visits, and preventing costly complications associated with chronic diseases. Regulatory support, growing acceptance among healthcare professionals, health insurance coverage, and strategic partnerships and investments among others are some of the major factors contributing to the overall growth of the digital therapeutics market and driving the market growth during the forecast period from 2024-2030.

Digital Therapeutics Market Dynamics:

As per the International Diabetes Federation 2022, in the year 2021, approximately 537 million people were living with diabetes, globally. As per the aforementioned source, the total number of patients suffering from diabetes is projected to grow to about 643 million patients by the year 2030 and about 783 million people by 2045.

Digital therapeutic applications (DTx) such as Blue Star, Diabeo System, Livongo Diabetes Program, and Tidepool, among others, use web-based applications or cloud platforms to provide an evidence-based, personalized, rapid point-of-care management of chronic, behavior-modifiable conditions, including diabetes mellitus. DTx can improve patient compliance, therapeutic success, and economic outcomes in diabetes management by enabling active patient engagement, lifestyle change, comprehensive medical care, and periodic monitoring of glycemic status. Thus, the rising prevalence of diabetes will increase the demand for digital therapeutic software which are used in the management and treatment of diabetes, thereby propelling the overall market of digital therapeutics.

The market is anticipated to be driven by rising smartphone adoption in both developed and developing nations, the affordability of digital health technology for patients and providers, and rising demand for patient-centered care and integrated healthcare systems. Kepios estimates that 4.27 billion people used the internet worldwide in April 2021, making up more than 60% of the world's population. It is anticipated that as this number rises, so will public awareness of smart health tracking. Additionally, it is projected that the COVID-19 pandemic, helpful regulatory actions, early indications of reimbursement, and the rising prevalence of chronic diseases will fuel market expansion.

The increasing focus of major key players on developing such technologically advanced software with easy access for physicians and patients is expected to propel the market during the forecast period. For instance, in July 2022, AmerisourceBergen Corporation launched DTx Connect, a fully integrated ordering, dispensing, and fulfillment platform that aims to facilitate patient access to physician-ordered therapeutics and diagnostics. The platform integrates with electronic medical records (EMR), giving physicians easy access to prescription and non-prescription therapies.

Therefore, the above-mentioned factors are contributing to the growth of the digital therapeutics market during the forecast period from 2024-2030.

However, cybersecurity and privacy concerns, unstable payment models, and others may restrict the digital therapeutics market growth.

Digital Therapeutics Market Segment Analysis:

Digital Therapeutics Market by Application (Prevention, Management, and Treatment), Indication (Diabetes, Obesity, Cardiovascular Diseases, Respiratory Diseases, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the indication segment of the digital therapeutics market, the obesity category is expected to amass a significant revenue share in the year 2023. This can be attributed to the increasing statistics of obesity across the globe.

The World Obesity Atlas 2022, published by the World Obesity Federation, predicts that one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. Obesity is a major public health challenge that affects almost every country in the world. Globally, obesity rates have been increasing steadily over the last three decades. In almost every region, there are now more people living with obesity than underweight, and if current numbers continue to rise, as many as 1 billion adults, or 12% of the world population, will be living with obesity by 2025. The above-mentioned source also stated that almost 2.3 billion children and adults were living with overweight and obesity, in 2022, globally and if current trends continue, 2.7 billion adults could be living with overweight or obesity by 2025.

World Health Organization (WHO) European Regional Obesity Report 2022, stated that overweight and obesity affect almost 60% of adults and nearly one in three children (29% of boys and 27% of girls) in the WHO European Region, in 2022.

The use of a digital therapeutics platform in people with obesity and metabolic syndrome can lead to a reduction in both weight and body mass index (BMI), thereby reducing the risk for comorbidities. Digital therapeutic platforms allow clinicians to deliver lifestyle-modification interventions remotely. These interventions have the potential to influence weight loss in people with obesity and metabolic syndrome through the delivery of evidence-based care even in settings that are resource-limited.

Thus, the increasing prevalence of obesity and overweight will increase the demand for digital therapeutics for managing and treating obesity and overweight.

The WDTx Platform by Wellthy Therapeutics Pvt Ltd. provides a 52-week lifestyle modification program focused on diet, physical activity, weight management, remote patient monitoring, glycemic control, and blood pressure control. The platform provides artificial intelligence-augmented healthcare tracking, evidence-backed content, and personalized health coach support.

Thus, the above-mentioned factors are likely to propel the demand for obesity-managing digital therapeutics, thereby contributing to the growth of the digital therapeutics market during the forecast period from 2024-2030.

North America is expected to dominate the overall Digital Therapeutics Market:

Among all the regions, North America is estimated to account for the largest share of the Digital Therapeutics market in the year 2023. This domination is due to the increasing demand for digital therapeutics among the physicians and patients in the region, the increasing patient pool suffering from chronic diseases, the rising demand for remote patient monitoring and telemedicine, the presence of key market players among the key factors that contribute to the growth of the digital therapeutics, among others will propel the market of digital therapeutics in North America.

The rising burden of the geriatric patient population in the region will increase the demand for digital therapeutics as elderly patients are more prone to chronic diseases. The U.S. Census Bureau, Population Projections, latest data reported that the number of Americans ages 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060, and the 65-and-older age group's share of the total population will rise from 16 percent to 23 percent.

The favorable regulatory authorities will propel the overall market of digital therapeutics in the region. For instance, in April 2020, the Food and Drug Administration of the US released guidelines and planned to expand the accessibility of digital therapeutic devices for psychiatric patients. It was aimed to subsidize those people who followed the guidelines and practiced social isolation without a clinic visit during the COVID-19 pandemic situation

Furthermore, the growing healthcare IT expenditure to advance infrastructure, technological literacy, readiness to adopt advanced technological solutions, favorable government initiatives, the emergence of startups, lucrative funding options growing smartphone penetration, and advancements in internet connectivity, will propel the demand for digital therapeutics in North America.

Some of the major players in this region are Proteus Digital Health, Inc., Omada Health, Inc., WellDoc, Inc., and Livongo Health, Inc.

Thus, all the above-mentioned factors will lead to an increase in the North America Digital Therapeutics market growth during the forecasting period of 2024-2030.

Digital Therapeutics Market Key Players:

Some of the key market players operating in the digital therapeutics market include Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc., CANARY HEALTH, Noom, Inc., Omada Health Inc., Welldoc, Inc., 2Morrow, Inc., ResMed, Teladoc Health, Inc., Fitbit Health Solutions, and others.

Recent Developmental Activities in the Digital Therapeutics Market:

In January 2023, Lupin Digital Health, a wholly-owned subsidiary of global pharma major Lupin Limited, launched its digital therapeutics solution, LYFE. LYFE is India's only evidence-based holistic heart care program that significantly reduces the risk of a heart attack and improves vitals and quality of life for cardiac patients

In May 2022, International digital therapeutics innovator, Sidekick Health, launched an integrated digital therapeutics solution for improving the outcomes of patients with Atopic Dermatitis (AD) in conjunction with Pfizer Inc. Sidekick and Pfizer will roll out their integrated digital therapeutics offering, launching first in the UK, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan later in 2022.

In June 2020, the FDA cleared the first video game for children with attention deficit hyperactivity disorder (ADHD), allowing Akili Interactive's EndeavorRx to be prescribed as a digital therapeutic.

In April 2021, Mahana Therapeutics, Inc. received the US FDA 510(K) marketing clearance for its Mahana Parallel Digital Cognitive Behavioral Therapy (CBT) mobile application, it is substantially equivalent to a marketed predicate device for Irritable Bowel Syndrome (IBS)

Key Takeaways from the Digital Therapeutics Market Report Study

Market size analysis for current digital therapeutics market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global digital therapeutics market.

Various opportunities are available for the other competitors in the digital therapeutics market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current digital therapeutics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for digital therapeutics market growth in the coming future?

Target Audience who can be benefited from this Digital Therapeutics Market Report Study

Digital therapeutics products providers

Research organizations and consulting companies

Digital therapeutics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in digital therapeutics

Various End-users who want to know more about the digital therapeutics market and the latest technological developments in the digital therapeutics market.

Frequently Asked Questions for the Digital Therapeutics Market:

1. What are digital therapeutics?

Digital Therapeutics (DTx) are evidence-based therapeutic interventions driven by software to prevent, manage, or treat a medical disorder or disease. In other words, DTx is a patient-facing software application that helps patients treat, prevent, or manage the disease and that has a proven clinical benefit.

2. What is the market for global digital therapeutics?

The global digital therapeutics market is estimated to grow at a CAGR of 27.73% during the forecast period from 2024 to 2030.

3. What are the drivers for the global digital therapeutics market?

The demand for digital therapeutics is primarily being heightened by the growing geriatric population prone to chronic diseases, the rising number of patients pool suffering from chronic diseases, the increasing usage of smartphones for digital therapeutics, the rising use of health monitoring apps, the cost-effectiveness of digital health technology for providers & patients, and increasing demand for integrated healthcare systems & patient-centric care among others, thereby contribute to the overall growth of the digital therapeutics market during the forecast period from 2024-2030.

4. Who are the key players operating in the global digital therapeutics market?

Some of the key market players operating in the digital therapeutics market include Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc., CANARY HEALTH, Noom, Inc., Omada Health Inc., Welldoc, Inc., 2Morrow, Inc., ResMed, Teladoc Health, Inc., Fitbit Health Solutions, and others.

5. Which region has the highest share in the digital therapeutics market?

North America is expected to dominate the overall digital therapeutics market during the forecast period from 2024-2030. Factors such as the growing prevalence of chronic disorders such as diabetes, cardiovascular diseases, and cancers, among others, and the increasing geriatric population prone to chronic diseases will positively impact the North American digital therapeutics market. Furthermore, high disposable income, sophisticated healthcare infrastructure, incremental healthcare expenditure, an increasing number of start-ups, a well-developed healthcare sector, and increasing investments for R&D, among others also helped the market growth in this region.

Table of Contents

1. Digital Therapeutics Market Report Introduction

2. Digital Therapeutics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Digital Therapeutics Market Key Factors Analysis

  • 4.1. Digital Therapeutics Market Drivers
    • 4.1.1. Growing demand for remote patient monitoring and mobile health applications
    • 4.1.2. Increasing prevalence of chronic diseases
    • 4.1.3. Advancements in digital healthcare, IoT, AI, and others
  • 4.2. Digital Therapeutics Market Restraints and Challenges
    • 4.2.1. Cybersecurity and privacy concerns
    • 4.2.2. Unstable payment models
  • 4.3. Digital Therapeutics Market Opportunities
    • 4.3.1. Increasing supportive initiatives and strategic alliances among the key players to grow the market of digital therapeutics

5. Digital Therapeutics Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Digital Therapeutics Market Layout

  • 6.1. By Application
    • 6.1.1. Prevention
    • 6.1.2. Management
    • 6.1.3. Treatment
  • 6.2. By Indication
    • 6.2.1. Diabetes
    • 6.2.2. Obesity
    • 6.2.3. Cardiovascular Diseases
    • 6.2.4. Respiratory Diseases
    • 6.2.5. Others
  • 6.3. By Geography
    • 6.3.1. North America Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.1.1. United States Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.1.2. Canada Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.1.3. Mexico Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.2. Europe Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.2.1. France Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.2.2. Germany Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.2.3. United Kingdom Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.2.4. Italy Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.2.5. Spain Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.2.6. Rest of Europe Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.3. Asia-Pacific Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.3.1. China Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.3.2. Japan Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.3.3. India Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.3.4. Australia Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.3.5. South Korea Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.3.6. Rest of the Asia-Pacific Digital Therapeutics Market Size in USD million (2021-2030)
    • 6.3.4. Rest of the World (RoW) Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.4.1. Middle East Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.4.2. Africa Digital Therapeutics Market Size in USD million (2021-2030)
      • 6.3.4.3. South America Digital Therapeutics Market Size in USD million (2021-2030)

7. Digital Therapeutics Market Company and Product Profiles

  • 7.1. Limbix Health, Inc.
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. GAIA AG
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. BigHealth
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. DarioHealth Corp
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. HYGIEIA
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Akili, Inc
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Pear Therapeutics (US), Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. CANARY HEALTH
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Noom, Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Omada Health Inc.
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Welldoc, Inc.
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. 2Morrow, Inc
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. ResMed
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Teladoc Health, Inc.
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Fitbit Health Solutions
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Digital Therapeutics Market in Global (2021-2030)
  • Table 3: Digital Therapeutics Market in Global by Application (2021-2030)
  • Table 4: Digital Therapeutics Market in Global by Indication (2021-2030)
  • Table 5: Digital Therapeutics Market in Global by Geography (2021-2030)
  • Table 6: Digital Therapeutics Market in North America (2021-2030)
  • Table 7: Digital Therapeutics Market in the US (2021-2030)
  • Table 8: Digital Therapeutics Market in Canada (2021-2030)
  • Table 9: Digital Therapeutics Market in Mexico (2021-2030)
  • Table 10: Digital Therapeutics Market in Europe (2021-2030)
  • Table 11: Digital Therapeutics Market in France (2021-2030)
  • Table 12: Digital Therapeutics Market in Germany (2021-2030)
  • Table 13: Digital Therapeutics Market in the United Kingdom (2021-2030)
  • Table 14: Digital Therapeutics Market in Italy (2021-2030)
  • Table 15: Digital Therapeutics Market in Spain (2021-2030)
  • Table 16: Digital Therapeutics Market in the Rest of Europe (2021-2030)
  • Table 17: Digital Therapeutics Market in Asia-Pacific (2021-2030)
  • Table 18: Digital Therapeutics Market in China (2021-2030)
  • Table 19: Digital Therapeutics Market in Japan (2021-2030)
  • Table 20: Digital Therapeutics Market in India (2021-2030)
  • Table 21: Digital Therapeutics Market in Australia (2021-2030)
  • Table 22: Digital Therapeutics Market in South Korea (2021-2030)
  • Table 23: Digital Therapeutics Market in Rest of Asia-Pacific (2021-2030)
  • Table 24: Digital Therapeutics Market in the Rest of the World (2021-2030)
  • Table 25: Digital Therapeutics Market in the Middle East (2021-2030)
  • Table 26: Digital Therapeutics Market in Africa (2021-2030)
  • Table 27: Digital Therapeutics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Digital Therapeutics Market in Global (2021-2030)
  • Figure 3: Digital Therapeutics Market in Global by Application (2021-2030)
  • Figure 4: Digital Therapeutics Market in Global by Indication (2021-2030)
  • Figure 5: Digital Therapeutics Market in Global by Geography (2021-2030)
  • Figure 6: Digital Therapeutics Market in North America (2021-2030)
  • Figure 7: Digital Therapeutics Market in the US (2021-2030)
  • Figure 8: Digital Therapeutics Market in Canada (2021-2030)
  • Figure 9: Digital Therapeutics Market in Mexico (2021-2030)
  • Figure 10: Digital Therapeutics Market in Europe (2021-2030)
  • Figure 11: Digital Therapeutics Market in France (2021-2030)
  • Figure 12: Digital Therapeutics Market in Germany (2021-2030)
  • Figure 13: Digital Therapeutics Market in the United Kingdom (2021-2030)
  • Figure 14: Digital Therapeutics Market in Italy (2021-2030)
  • Figure 15: Digital Therapeutics Market in Spain (2021-2030)
  • Figure 16: Digital Therapeutics Market in the Rest of Europe (2021-2030)
  • Figure 17: Digital Therapeutics Market in Asia-Pacific (2021-2030)
  • Figure 18: Digital Therapeutics Market in China (2021-2030)
  • Figure 19: Digital Therapeutics Market in Japan (2021-2030)
  • Figure 20: Digital Therapeutics Market in India (2021-2030)
  • Figure 21: Digital Therapeutics Market in Australia (2021-2030)
  • Figure 22: Digital Therapeutics Market in South Korea (2021-2030)
  • Figure 23: Digital Therapeutics Market in Rest of Asia-Pacific (2021-2030)
  • Figure 24: Digital Therapeutics Market in the Rest of the World (2021-2030)
  • Figure 25: Digital Therapeutics Market in the Middle East (2021-2030)
  • Figure 26: Digital Therapeutics Market in Africa (2021-2030)
  • Figure 27: Digital Therapeutics Market in South America (2021-2030)
  • Figure 28: Market Drivers
  • Figure 29: Market Barriers
  • Figure 30: Marker Opportunities
  • Figure 31: PORTER'S Five Force Analysis